Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Vertex Pharmaceuticals Incorporated
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
A study in children aged 6 Through 11 Years With Cystic Fibrosis to assess the efficacy and safety of a combination of two experimental drugs
To evaluate the efficacy of lumacaftor in combination with ivacaftor in subjects aged 6 Through 11 years with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
A Pilot Open-Label Study to Investigate the Safety and Anti-inflammatory Effects of VX-765, an Orally Administered Interleukin-1β Converting Enzyme Inhibitor, in Patients with Muckle-Wells Syndrome
Investigate safety/tolerability, anti-inflammatory effect and pharmacokinetics of VX-765 in patients with Muckle-Wells Syndrome.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with Lumacaftor in Combination with Ivacaftor
To evaluate the long term safety and tolerability of lumacaftor in combination with ivacaftor in subjects aged 6 years and older with cystic fibrosis (CF), homozygous for the F508del CFTR mutation, wh...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation
To evaluate the efficacy of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CF transmembrane conductance regulator (CFTR) mutation
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
A study to investigate the safety and effectiveness of telaprevir in combination with peginterferon alfa-2a and ribavirin in treating chronic hepatitis C virus infection in subjects who are co-infected with hepatitis C virus and immunodeficiency virus (HIV)
To assess the hepatitis C antiviral efficacy of telaprevir, peginterferon alfa-2a, and ribavirin
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
• To evaluate the efficacy of VX 509 across a range of doses • To evaluate the early effect of VX 509 administration on joint structures as assessed by magnetic resonance imaging (MRI)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
A study in people with Cystic Fibrosis ( a rare hereditary pulmonary disease) to assess the efficacy and safety of a combination of two experimental drugs Estudio en personas con Fibrosis Quística (una rara enfermedad pulmonar hereditaria) para evaluar la eficacia y seguridad de la combinación de dos fármacos experimentales
To evaluate the efficacy of lumacaftor in combination with ivacaftor through Week 24 in subjects with Cystic Fibrosis who are homozygous for the F508del-CFTR mutation Evaluar la eficacia de luma...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
To evaluate the efficacy, safety, and tolerability of VX-765 to treat seizures in subjects with treatment resistant partial epilepsy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
Lumacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis Who Have an A455E-CFTR Mutation
To evaluate the efficacy of LUM/IVA in subjects with CF 12 years of age and older who have at least one A455E mutation.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Vertex Pharmaceuticals Incorporated
MAJ Il y a 5 ans
A study in people with Cystic Fibrosis (a rare hereditary pulmonary disease) to assess the long-term efficacy and safety of a combination of two experimental drugs
To evaluate the long term safety and tolerability of lumacaftor in combination with ivacaftor in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the for the F508del-CFTR mut...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
Suivant